Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin

Ladha, Abdullah; Mannis, Gabriel N.; Muffly, Lori

doi:10.1080/10428194.2020.1827247

Cited by 12 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar occurrences have also been observed with the use of inotuzumab ozogamicin. 92,93 A comprehensive review published in 2016 summarized key clinical toxicities of other approved and developmental ADCs. 1 In general, their findings showed peripheral neuropathy and neutropenia induced by MMAE, which is consistent with adverse events listed for those approved ADCs carrying an MMAE payload.…”

Section: Challenges In the Development Of Adcsmentioning

confidence: 99%

Targeting cancer with antibody-drug conjugates: Promises and challenges

Dean

Luo

Twomey

et al. 2021

mAbs

115

View full text Add to dashboard Cite

Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the U.S. Food and Drug Administration (FDA) has approved ten ADCs, namely Adcetris®, Kadcyla®, Besponsa®, Mylotarg®, Polivy®, Padcev®, Enhertu®, Trodelvy®, Blenrep®, and Zynlonta™ as monotherapy or combinational therapy for breast cancer, urothelial cancer, myeloma, acute leukemia, and lymphoma. In addition, over 80 investigational ADCs are currently being evaluated in approximately 150 active clinical trials. Despite the growing interest in ADCs, challenges remain to expand their therapeutic index (with greater efficacy and less toxicity). Recent advances in the manufacturing technology for the antibody, payload, and linker combined with new bioconjugation platforms and state-of-the-art analytical techniques are helping to shape the future development of ADCs. This review highlights the current status of marketed ADCs and those under clinical investigation with a focus on translational strategies to improve product quality, safety, and efficacy.

show abstract

Section: Challenges In the Development Of Adcsmentioning

confidence: 99%

Targeting cancer with antibody-drug conjugates: Promises and challenges

Dean

Luo

Twomey

et al. 2021

mAbs

115

View full text Add to dashboard Cite

show abstract

“…Based on the results of a single-center retrospective analysis, the administration of GO prior to allogeneic transplantation has been considered to be a risk for the development of sinusoidal obstruction syndrome/sinusoidal obstruction syndrome (VOD/SOS) [ 126 ]. A short period of time between GO administration and allogeneic transplantation has also been considered to be a risk factor for the development of VOD/SOS [ 127 ]. However, with the recent trend toward the use of less intense conditioning regimens and the use of reduced or fractionated doses of GO, it is now believed that GO administration prior to allogeneic transplantation should not necessarily be avoided [ 128 ].…”

Section: Antibody–drug Conjugates For Amlmentioning

confidence: 99%

New Therapeutic Strategies for Adult Acute Myeloid Leukemia

Ishii

Yano

2022

Cancers

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a genetically heterogeneous hematological malignancy. Chromosomal and genetic analyses are important for the diagnosis and prognosis of AML. Some patients experience relapse or have refractory disease, despite conventional cytotoxic chemotherapies and allogeneic transplantation, and a variety of new agents and treatment strategies have emerged. After over 20 years during which no new drugs became available for the treatment of AML, the CD33-targeting antibody–drug conjugate gemtuzumab ozogamicin was developed. This is currently used in combination with standard chemotherapy or as a single agent. CPX-351, a liposomal formulation containing daunorubicin and cytarabine, has become one of the standard treatments for secondary AML in the elderly. FMS-like tyrosine kinase 3 (FLT3) inhibitors and isocitrate dehydrogenase 1/2 (IDH 1/2) inhibitors are mainly used for AML patients with actionable mutations. In addition to hypomethylating agents and venetoclax, a B-cell lymphoma-2 inhibitor is used in frail patients with newly diagnosed AML. Recently, tumor protein p53 inhibitors, cyclin-dependent kinase inhibitors, and NEDD8 E1-activating enzyme inhibitors have been gaining attention, and a suitable strategy for the use of these drugs is required. Antibody drugs targeting cell-surface markers and immunotherapies, such as antibody–drug conjugates and chimeric antigen receptor T-cell therapy, have also been developed for AML.

show abstract

“…On meta-analysis, the relative risk of high-grade transaminitis in patients with breast cancer treated with T-DM1 (anti-HER2) was more than double that of controls [ 74 ]. Exposure to anti-CD agents, gemtuzumab ozagamicin, and inotuzumab ozagamicin, increases the risk of hepatic veno-occlusive disease (VOD) after stem cell transplant for treatment of leukemia, and is associated with high mortality in severe cases [ 75 ]. Patients treated with anti-CD20 agents (rituximab, obinutuzumab, and ofatumumab) for non-Hodgkin lymphoma are at very high risk of hepatitis B virus (HBV) reactivation that, if unrecognized, can lead to life-threatening hepatic dysfunction; monitoring and anti-viral prophylaxis for those at high risk are recommended [ 76 ].…”

Section: Targeted Antibodiesmentioning

confidence: 99%

Cancer Immunotherapies: What the Perioperative Physician Needs to Know

et al. 2022

View full text Add to dashboard Cite

Purpose of ReviewFor patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. Recent Findings The perioperative period is a poignant moment in the journey of a patient with cancer, potentially deemed most influential compared to other moments in the care continuum. Several immunotherapeutic medications have been employed near the time of surgery to potentially increase effectiveness. Of the various drug classes, including immune checkpoint inhibitors, cytokines, toll-like receptor agonists, and oncolytic viruses, among others, several notable immunerelated adverse effects were noted. They range from minor effects to more serious ones, such as renal failure, myocarditis, and tumor growth. Summary Surgery and immunotherapy are often employed in combination for primary treatment and prevention of cancer recurrence. Careful review and consideration of the pharmacokinetics, pharmacodynamics, and toxicities of immunotherapy benefit the perioperative physician and their patients.

show abstract

Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin

Cited by 12 publications

References 30 publications

Targeting cancer with antibody-drug conjugates: Promises and challenges

Targeting cancer with antibody-drug conjugates: Promises and challenges

New Therapeutic Strategies for Adult Acute Myeloid Leukemia

Cancer Immunotherapies: What the Perioperative Physician Needs to Know

Contact Info

Product

Resources

About